New data at astro 2024 shows castle biosciences' decisiondx®-scc test provides more precise risk stratification than bwh staging alone to guide intensified treatment for immune suppressed patients with high-risk cutaneous squamous cell carcinoma

Friendswood, texas--(business wire)---- $cstl #astro--castle will share data at astro24 showing its decisiondx-scc test can provide impactful risk stratification in high-risk scc patient sub-populations.
CSTL Ratings Summary
CSTL Quant Ranking